Protein A Resin Market To Touch Usd 1,020.7 Million In 2030

By Author: Swati Sharma
Total Articles: 13
Comment this article

The growth of this industry is primarily ascribed to the increasing occurrence of chronic ailments as well as the mounting elderly populace.

Moreover, the industry is also driven by the increasing funding for patient-based research, coupled with the growing research activities to address unmet medicinal requirements in different therapeutic areas.

In this industry, the acceptance of partnership and collaboration tactics by various companies to develop improved next-generation protein A resins, coupled with the introduction of new products are the major trends witnessed.

Moreover, various private and public establishments are investing in protein-based research programs to enhance therapeutic methods. In addition, the rising occurrence of chronic illnesses would boost the requirement for new therapeutic candidates for ailment management.

In recent years, the recombinant category, based on source, led the industry, and it will further advance at a faster rate, of 7.5%, in the coming years. This is mainly because recombinant protein A resins are extensively employed in the monoclonal antibody ...
... downstream processing.

The agarose-based category, based on matrix, was the largest contributor to the protein A resin market in recent years, and it will propel at the fastest rate in the coming years. This is because agarose-based resins comprise hydrophobic and ionic groups that interact with the composite of interest. Therefore, various antibody makers favor utilizing agarose-based resins.

The antibody purification category, on the basis of application, will advance at a faster rate during this decade. This will be mainly because of the surging need and high production of antibodies, mainly monoclonal antibodies for therapeutic uses.

The biotechnology and pharmaceutical industries category, based on end-user, will propel at a faster pace in the years to come. This is because these sectors utilize an enormous quantity of protein A resins in the antibody manufacturing process.

North America was the largest contributor to the industry in the past few years. This is primarily because of the growing requirement for protein-based therapeutics to treat different chronic conditions, coupled with the increasing count of the FDA approved biopharmaceuticals in this region.

APAC is likely to advance at the fastest rate, of 7.8%, in the years to come. This will be mainly because of the surging adoption of protein A resins in drug discovery, the growing count of life sciences research activities, and improvements in technologies in this region.

It is because of the increasing aging populace and rise in the prevalence of chronic ailments, the protein A resin industry will advance continuously in the coming years.

SOURCE: P&S Intelligence